In osteosarcoma, inhibition of FAM83H inhibited in vivo growth of KHOS/NP osteosarcoma cells, and the PARP inhibitor, olaparib, potentiated the anticancer effect of doxorubicin in KHOS/NP osteosarcoma cells [6, 22]. This evidence concerns the gene PARP1 and osteosarcoma.